Figure 5. Some ALK-TKI–resistant clinical samples show decreased MIG6 levels.

(A) Microarray data were analyzed from 42 patients with ALK-positive lung cancer who underwent lung surgery at our hospital (GSE128309). Relative expression levels of MIG6 and EGFR (log₂) are shown. (B) Clinical course of patient JFCR-028 and JFCR-426. PR, partial response. (C) RT-qPCR of ERRFI1 was performed using clinical samples. Each point represents the relative mRNA expression of MIG6/GAPDH shown as mean ± SD of 3 technical replicates; ***P < 0.001 (Student’s t test). (D) Immunoblot analysis of MIG6 in JFCR-028-3 or 028-5 cells. Similar experiments were performed twice.